Q-omics provides the consensus-scored RNF225 profile across patient tissues and cancer cell-line models. RNF225 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, RNF225 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, RNF225 RNA expression shows 12,308 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SKCM, COAD, and THYM as cancer lineages where RNF225 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF225 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF225 survival associations across molecular data types. RNF225 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF225 RNA expression–survival associations across cancer types. High RNF225 expression shows unfavorable associations in SKCM, COAD, MESO and LIHC, but favorable associations in HNSC and GBM. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for RNF225 RNA expression.
This table summarizes RNF225 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RNF225. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF225 shows lower tumor expression in HNSC and KIRC and higher tumor expression in COAD, THCA, LUAD and LUSC. The COAD box plot shows higher RNF225 RNA expression in tumor versus normal tissue (log2 FC = +0.253, t-test p < 0.001).
This table shows molecular features associated with RNF225 in patient tissues and cancer cell lines. In patient samples, RNF225 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF225 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT.
